Skip to main content
BOUT logo

Innovator IBD Breakout Opportunities ETF (BOUT) Fund Overview

Educational signal · not a buy or sell recommendation · How to read this

$43.06 +$0.4303 (+1.01%)
Vol: 651|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Innovator IBD Breakout Opportunities ETF (BOUT) trades at $43.06. The Innovator IBD Breakout Opportunities ETF (BOUT) aims to mirror the investment performance of the IBD Breakout Stocks Index. Sector: Financials.

Price as of · Last analyzed: Mar 18, 2026
The Innovator IBD Breakout Opportunities ETF (BOUT) aims to mirror the investment performance of the IBD Breakout Stocks Index. The fund focuses on identifying stocks poised for significant price increases beyond their resistance levels, utilizing Investor's Business Daily research.

Analyst Coverage for BOUT: BOUT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the BOUT film Every key number, told as a short cinematic story — just press play. ~2 min

Innovator IBD Breakout Opportunities ETF (BOUT) Financial Services Profile

IPO Year2018

Innovator IBD Breakout Opportunities ETF (BOUT) offers investors exposure to a portfolio of stocks identified by the IBD Breakout Stocks Index as poised for significant price appreciation. The ETF leverages Investor's Business Daily's research to target securities exhibiting breakout potential within various market conditions.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for BOUT?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

The Innovator IBD Breakout Opportunities ETF (BOUT) presents a targeted investment vehicle for those seeking exposure to stocks identified as having near-term breakout potential. The fund's value proposition hinges on the continued efficacy of the IBD Breakout Stocks Index in identifying securities poised for price appreciation. A key driver is the potential for capital appreciation from the underlying holdings. However, the fund's performance is susceptible to market volatility and the accuracy of the index's selection methodology. The ETF's small market capitalization of $0.01 billion indicates a higher risk profile compared to larger, more established ETFs. Success depends on the fund's ability to consistently identify and capture gains from breakout stocks, while effectively managing downside risk.

Based on FMP financials and quantitative analysis

BOUT Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

BOUT's investment strategy is based on the IBD Breakout Stocks Index, leveraging decades of Investor's Business Daily research.

  • The ETF targets stocks poised for price breakouts, aiming to capture short-term capital appreciation.
  • BOUT offers a focused approach to growth investing, concentrating on stocks exhibiting specific technical and fundamental characteristics.
  • The fund's performance is directly tied to the accuracy and effectiveness of the IBD Breakout Stocks Index methodology.
  • BOUT's small market capitalization of $0.01 billion may present liquidity considerations for larger investors.

Who Are BOUT's Competitors?

BOUT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
BPAY iShares FinTech Active ETF $24.50 0.00% $8.33M —
CHPS Xtrackers Semiconductor Select Equity ETF $94.28 +0.39% $118M —
FLAO AllianzIM U.S. Equity 6 Month Floor5 Apr/Oct ETF $28.91 +0.23% $8.67M —
GXDW Global X - Dorsey Wright Thematic ETF $25.54 +0.85% $8.47M —
IBAT iShares Energy Storage & Materials ETF $42.21 +0.50% $13.5M —
BLK BlackRock, Inc. $1066.45 +0.64% $165B 51 5-pillar
BX Blackstone Inc. $111.64 -0.09% $136B 68 5-pillar
APOS Apollo Global Management, Inc. $25.59 0.00% $74.8B 56 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BOUT's Key Strengths?

Unique investment strategy focused on breakout stocks.

  • Leverages the research expertise of Investor's Business Daily.
  • Potential for high capital appreciation.
  • Transparent and rules-based index methodology.

What Are BOUT's Weaknesses?

Small market capitalization may limit liquidity.

  • Performance is highly dependent on the accuracy of the IBD Breakout Stocks Index.
  • Higher volatility compared to broader market ETFs.
  • Concentrated investment focus may increase risk.

What Are the Key Risks for BOUT?

Market volatility may negatively impact the fund's performance.

  • Changes in the IBD Breakout Stocks Index methodology.
  • Competition from other thematic ETFs.
  • Economic downturn may reduce investor demand for growth stocks.

What Are BOUT's Competitive Advantages?

  • Proprietary Index: The IBD Breakout Stocks Index is a unique and proprietary index that provides a differentiated investment strategy.
  • Brand Reputation: Investor's Business Daily has a strong reputation for its research and analysis, which enhances the credibility of BOUT.
  • First-Mover Advantage: BOUT was one of the first ETFs to focus specifically on breakout stocks, giving it a competitive advantage.

What Does BOUT Do?

The Innovator IBD Breakout Opportunities ETF (BOUT) was created to track the investment results of the IBD Breakout Stocks Index. This index is designed to identify stocks that are on the verge of experiencing a sustained period of price growth, exceeding their established 'resistance level.' The ETF's strategy is rooted in the research methodology developed by Investor's Business Daily (IBD) over several decades. IBD's approach combines fundamental and technical analysis to pinpoint companies demonstrating the potential for significant upward price movement. BOUT provides investors with a vehicle to access a diversified portfolio of these breakout stocks, aiming to capitalize on their anticipated growth. The ETF's investment decisions are guided by the index's rules-based approach, which considers various market conditions to refine its stock selection process. The fund's objective is to deliver returns that closely align with the performance of the IBD Breakout Stocks Index, offering investors a way to participate in the potential upside of carefully selected growth stocks. BOUT operates within the broader asset management industry, offering a specialized investment product focused on a specific growth-oriented strategy.

What Products and Services Does BOUT Offer?

  • Tracks the investment results of the IBD Breakout Stocks Index.
  • Identifies stocks poised for significant price increases.
  • Leverages Investor's Business Daily research.
  • Focuses on stocks exceeding their recent 'resistance level'.
  • Considers various market conditions in stock selection.
  • Provides exposure to a portfolio of potential breakout stocks.

How Does BOUT Make Money?

  • Generates revenue through management fees charged on assets under management (AUM).
  • AUM growth is driven by investment performance and investor inflows.
  • The fund's profitability depends on its ability to attract and retain investors.

What Industry Does BOUT Operate In?

The Innovator IBD Breakout Opportunities ETF (BOUT) operates within the asset management industry, specifically in the exchange-traded fund (ETF) segment. The ETF market has experienced significant growth in recent years, driven by increasing investor demand for diversified, low-cost investment vehicles. BOUT's focus on breakout stocks differentiates it from broader market ETFs, catering to investors seeking higher growth potential. However, this focus also exposes the fund to greater volatility and risk compared to more diversified strategies. The competitive landscape includes a variety of ETFs with different investment mandates, requiring BOUT to effectively market its unique approach to attract and retain investors.

Who Are BOUT's Key Customers?

  • Retail investors seeking growth-oriented investment strategies.
  • Financial advisors looking for specialized ETF products.
  • Institutional investors seeking exposure to breakout stocks.
Model self-rating on this text: 81% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
  • ● This is an etf, not an operating company

MoonshotScore History

Recorded daily since 2026-08-23 · 42 snapshots

2026-08-23 47
2026-08-31 47
2026-09-08 47
2026-09-16 47
2026-09-24 47
2026-10-04 47
2026-10-05 47

What changed?

The score has stayed at 47.

Over the same 30 days the stock moved -3.6%.

Net selling

Insider Activity

2 transactions · 0 purchases, 2 sales, 0 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

BOUT Financials

Bull Case vs Bear Case

Bull Case

  • Unique investment strategy focused on breakout stocks.
  • Leverages the research expertise of Investor's Business Daily.
  • Potential for high capital appreciation.
  • Transparent and rules-based index methodology.

Bear Case

  • Small market capitalization may limit liquidity.
  • Performance is highly dependent on the accuracy of the IBD Breakout Stocks Index.
  • Higher volatility compared to broader market ETFs.
  • Concentrated investment focus may increase risk.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

BOUT Latest News

BOUT Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BOUT.

Price Targets

Wall Street price target analysis for BOUT.

BOUT MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BOUT; grades run from A+ (80-100) to F (below 30).

BOUT Financials Stock FAQ

How does Innovator IBD Breakout Opportunities ETF select stocks for its portfolio?

The Innovator IBD Breakout Opportunities ETF (BOUT) selects stocks based on the rules-based methodology of the IBD Breakout Stocks Index. The selection process considers factors such as earnings growth, relative strength, and price and volume action.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • The performance of BOUT is highly dependent on the accuracy of the IBD Breakout Stocks Index.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis